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ABSTRACT: We used tryptophan substitutions to characterize the beta M3 transmembrane domain (âTM3)
of the acetylcholine receptor (AChR). We generated 15 mutants with tryptophan substitutions within the
âTM3 domain, between residues R282W and I296W. The various mutants were injected into Xenopus
oocytes, and expression levels were measured by [125I]-R-bungarotoxin binding. Expression levels of the
M288W, I289W, L290W, and F293W mutants were similar to that of wild type, whereas the other mutants
(R282W, Y283W, L284W, F286W, I287W, V291W, A292W, S294W, V295W, and I296W) were
expressed at much lower levels than that of wild type. None of these tryptophan mutants produced peak
currents larger than that of wild type. Five of the mutants, L284W, F286W, I287W, V295W, and I296W,
were expressed at levels <15% of the wild type. I296W had the lowest expression levels and did not
display any significant ACh-induced current, suggesting that this position is important for the function
and assembly of the AChR. Tryptophan substitution at three positions, L284, V291, and A292, dramatically
inhibited AChR assembly and function. A periodicity analysis of the alterations in AChR expression at
positions 282-296 of the âTM3 domain was consistent with an R-helical structure. Residues known to
be exposed to the membrane lipids, including R282, M285, I289, and F293, were all found in all the
upper phases of the oscillatory pattern. Mutants that were expressed at lower levels are clustered on one
side of a proposed R-helical structure. These results were incorporated into a structural model for the
spatial orientation of the TM3 of the Torpedo californica â subunit.
The nicotinic acetylcholine receptor (AChR)1 from muscle
and Torpedo electroplax is an integral membrane protein
comprised of four homologous polypeptide subunits in the
stoichiometry of R2âçä (1-5). A model for the AChR
topology obtained from hydrophobicity profiles indicates that
each of the subunits possesses at least four transmembrane
domain regions, designated as M1, M2, M3, and M4 (or TM1
to TM4), with both N- and C-termini located on the
extracellular side (6, 7). Most of the studies that have
characterized the role of these transmembrane domains have
focused on the TM2 domain (8-18). Of these putative
transmembrane regions, the TM2 and TM1 segments from
each subunit participate in forming the wall-lining pore of
the ion channel. The TM3 and TM4 regions have the most
contact with the lipid interface (19, 20). The TM4 domain
is the most hydrophobic, and its side chains are the least
conserved. It has been shown that mutations of lipid-exposed
residues within TM4 can dramatically alter the AChR
channel gating kinetics (21-26).
Analysis of TM3 demonstrated that this lipid-exposed
domain is a key component of the AChR channel gating
machinery. Wang and co-workers found that the V285I
mutation in TM3 in the muscle-type R-subunit causes a
congenital myasthenic syndrome (27). Tryptophan substitu-
tions at the lipid-exposed positions within TM3 of the
ç-subunit have been reported to increase the macroscopic
response of the Torpedo AChR (28). Furthermore, replace-
ment with hydrophobic amino acids at the 8¢ position of TM3
of the muscle-type AChR further suggested that this domain
contributes to the channel gating (29). A more recent study
provided additional evidence suggesting that the RTM3
domain plays a role in channel gating and that lipid-exposed
domains within this region regulate the differential modula-
tion of ion channel function in various AChR species (30).
These previous studies clearly indicate that the TM3 trans-
membrane domain plays an important role in the AChR
gating mechanism. However, the detailed secondary structure
and spatial orientation of this transmembrane segment remain
unknown.
The three-dimensional organization of the AChR has been
characterized at 9 Å resolution by electron microscopy of
tubular crystals of Torpedo postsynaptic membranes embed-
ded in amorphous ice (2). At this resolution, a single rod
was visible around the central axis of the transmembrane
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Published on Web 07/15/2004domain (presumably TM2) within each subunit, suggesting
that TM2 is the only transmembrane segment that forms an
R-helical structure. Due to the absence of similar density
within the lipid-facing portion of the AChR, it was originally
suggested that the TM1, TM3, and TM4 domains existed in
a â-sheet structure (2). In a more recent study, the same
authors provided a new interpretation where all transmem-
brane segments were proposed to be R-helical structures (31).
The pattern of labeling of TM3 and TM4 with the photo-
activated hydrophobic probe 3-(trifluoromethyl)-3-m-[125I]-
iodophenyldiazirine ([125I]-TID) was found to be consistent
with an R-helical structure (19, 20). Fourier transform
infrared (FTIR) spectroscopy studies of receptors in which
the extracellular and intracellular portions were removed by
proteinase K digestion suggested that the transmembrane
domains of the receptors include a mixture of R-helical and
â structures (32). A more recent FTIR spectroscopy analysis
of affinity-purified receptors, in which the nonmembrane
domains were digested with Pronase and proteinase K,
indicated that the secondary structures of the AChR trans-
membrane domains are predominantly R-helical (33). H
NMR analysis of a three-dimensional structure of a synthetic
polypeptide, corresponding to the RTM3 of Torpedo, sug-
gested that this domain forms an R-helical structure (34).
Moreover, tryptophan-scanning mutagenesis of the TM3 (35)
and TM4 (26) transmembrane segments of the R subunit of
the Torpedo californica AChR also suggests that both
domains are R-helical structures.
In this study, we have characterized the TM3 transmem-
brane region of the â-subunit of the T. californica AChR.
Fifteen positions (âR282 to âI296) of the putative âTM3
domain were sequentially replaced with tryptophan. The
periodicity of receptor expression levels as a function of
tryptophan substitution suggested that this region exists as
an R-helical structure. Tryptophan replacements at three
positions thought to be in contact with the lipid environment
(M285, I289, and F293) resulted in AChR expression levels
similar to that of the wild-type receptor. Tryptophan substitu-
tion at four positions presumed to be oriented toward the
interior of the protein significantly inhibited channel function
(L284, V291, and A292) and/or receptor assembly (I296).
These results provide new information regarding the spatial
orientation of the TM3 of the T. californica â subunit and
its contribution to AChR assembly and function.
MATERIALS AND METHODS
Mutation of the â Subunit of the T. californica AChR. Site-
directed mutagenesis of the â subunit of the AChR was
carried out by mismatch amplification using two sequential
rounds of polymerase chain reaction (PCR) (36). The coding
region of the â subunit of T. californica AChR was subcloned
from PR (37) into the HindIII and EcoRI sites of the
pGEM3Z(-) vector (Promega, Madison, WI). Mutagenic
primers included the Trp codon (TGG) in place of the wild-
type codon at the desired positions and extended 11-13
bases on each side of the mismatched region. The primers
were synthesized by Gibco BRL (Gaithersburg, MD). Each
PCR included 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5
mM MgCl2, 0.01% gelatin, 200 nM of each deoxynucleotide,
100 ng of DNA template, 1 íM of each primer, and 2.0 units
of Taq DNA polymerase (Promega, Madison, WI) in a final
volume of 100 íL. Amplification reactions were performed
in a DNA thermal cycler (Perkin-Elmer-Cetus) programmed
for 30 cycles of a three-step protocol: 3 min at 94 °C, 1
min at 50 °C, and 3 min at 72 °C. The PCR reactions were
subjected to electrophoresis on agarose gels, and the desired
PCR products were excised from the gels and purified with
Gene-Clean (Bio 101, La Jolla, CA). These mutant DNA
fragments were then used in a second fusion PCR. The fusion
product was purified from the gel with Gene-Clean and
digested with BspE1 and Nco1 (New England BioLabs,
Beverly, MA). The plasmid containing the coding region of
the â subunit was also digested with BspE1 and Nco1. The
mutant fragment was then inserted into the â subunit with
T4 DNA ligase (New England Biolabs, Beverly, MA).
Tryptophan substitutions at positions R282, Y283, L284,
F286, I287, L290, S294, and V295 were created using the
QuickChange site-directed mutagenesis kit (Stratagene, La
Jolla, CA). Mutations were confirmed by sequence analysis
performed at the DNA Sequencing Facility in the Section
of Evolution and Ecology, University of California, Davis,
CA. To exclude the possibility of secondary mutations, the
entire coding region of the â subunit was subjected to DNA
sequence analysis. For mutations prepared by mismatch
amplification or overlap extension, the entire mutagenized
fragment was sequenced from both the 3¢ and 5¢ directions.
Expression in Xenopus laeVis Oocytes. RNA transcripts
were synthesized in vitro as described previously (21).
Briefly, RNA transcripts corresponding to the R, â, ç, and
ä subunits were injected in Xenopus oocytes in a 2:1:1:1
ratio (10 ng/oocyte at a concentration of 0.2 íg/íL).
Voltage Clamping. Three days after mRNA injection,
ACh-induced currents were recorded with a two-electrode
voltage clamp using the Gene Clamp 500 amplifier (Axon
Instruments, Foster City, CA). Electrodes were filled with 3
M KCl, and resistances were <2M ¿. Impaled oocytes in
the recording chamber were perfused at a rate of 0.5 mL/s
with MOR-2 buffer [115 mM NaCl, 2.5 mM KCl, 5 mM
MgCl2,1m MN a 2HPO4,5m MN-(2-hydroxyethyl)pipera-
zine-N¢-2-ethanesulfonic acid (HEPES), and 0.2 mM CaCl2
(pH 7.4)]. To determine dose-response curves for each
oocyte, membrane potential was held at -70 mV. Membrane
currents were sampled at 4 kHz and filtered at 2 kHz using
the DigiData 1200 interface (Axon Instruments, Union City,
CA). The Whole Cell Program 2.3 (kindly provided by Dr.
J. Dempster, University of Strathclyde, U.K.) running on a
Pentium III-based computer was used for data acquisition.
Prism version 3.0 (GraphPAD Software, San Diego, CA)
software was utilized for data analysis and curve fitting. Peak
currents at six ACh concentrations (1-300 íM) were used
to produce the dose-response curves. The data for the dose-
response curves were fit using a curve of the form Y ) 100/
[1 + (EC50/A)n]. The EC50 and Hill coefficient values for
individual oocytes were averaged to generate final estimates.
[125I]-R-Bungarotoxin Binding Assay. The expression of
nAChR in the oocyte membrane was determined by measur-
ing the binding of [125I]-R-bungarotoxin (Amersham Life
Sciences, Arlington Heights, IL) to intact oocytes, as
described previously (21). After macroscopic currents were
recorded, four to twelve oocytes expressing each mutation
were incubated in 10 nM [125I]-R-bungarotoxin ([125I]-BTX)
with 5 mg/mL bovine serum albumin in MOR-2 at room
temperature for 2 h. Excess toxin was then removed by
washing five times with 1 mL of MOR-2. To determine the
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was analyzed immediately after voltage clamping using a
Beckman Gamma 5500. Noninjected oocytes were used as
a control to determine background nonspecific binding. The
standard curve was defined by counting 0-20 íLo f1n M
[125I]-BTX solution (equivalent to 0-20 fmol). Using this
approach, the normalized channel response to ACh-induced
current (nanoamperes) per femtomole of surface R-BTX
binding sites was determined.
Modeling Methods. The structural models for the âÆM3
domain was examined using Biomer V1.0 alpha (see http://
www.scripps.edu/nnwhite/B). The structures were mini-
mized using the Fletcher-Reeves conjugated gradient al-
gorithm (<2000 iterations). The minimized pdb structures
generated in Biomer V1.0 alpha were then analyzed using
Accelrys DS ViewerPro 5.0 (www.accelrys.com). The
periodicity values for the expression levels of âÆM3 mutants
were estimated by performing the first derivative for each
amino acid position and estimating the distance between the
zeros for all positions using Graph Pad Software.
RESULTS
Expression of âM3 Mutants. Fifteen residues, from R282
to I296, within the TM3 domain of the â subunit of T.
californica AChR were individually replaced with tryp-
tophan. One double tryptophan mutant, I289W/L293W, was
also generated. mRNA transcripts were synthesized and
injected into X. laeVis oocytes, and the level of cell-surface
expression of mutant AChRs was assessed by 125I-BTX
binding analysis, as described in Materials and Methods. The
M288W, I289W, L290W, and F293W mutants were ex-
pressed at levels similar to that of wild type (Table 1). The
L284W, F286W, I287W, V295W, and I296W mutants were
expressed at the lowest levels (<15% of wild-type expression
levels). The M285W mutant was expressed at somewhat
higher levels than wild type, and the double mutant I289W/
L293W exhibited no detectable 125I-BTX binding on the
surface of oocytes. These results suggest that the âTM3
transmembrane domain can tolerate a single substitution of
a bulky hydrophobic side chain at all 15 positions but cannot
tolerate a double tryptophan substitution at positions I289
and F293 (see Table 1).
Electrophysiological Characterization of the âM3 Mu-
tants: Effect on Macroscopic Current Response. Figure 1
shows families of current traces elicited by progressive
increases in ACh concentration (1, 3, 10, 30, 100, and 300
Table 1: Functional Analysis of âM3 Mutantsa
nAChR
type
expression
level (fmol)
EC50
(íM)
Hill
coeficient
Imax
(nA)
normalized response
(nA/fmol)
wild type 4.1 ( 0.7 20 ( 2 1.4 ( 0.3 2285 ( 354 606 ( 58
R282W 0.9 ( 0.2c 30 ( 1c 1.17 ( 0.03 1934 ( 336 2506 ( 473d
Y283W 1.3 ( 0.2c 13 ( 3 1.24 ( 0.07 1038 ( 264b 754 ( 107
L284W 0.30 ( 0.05d 45 ( 4d 1.37 ( 0.09 209 ( 70d 810 ( 157
M285W 6 ( 1c 42 ( 6d 1.4 ( 0.1 1031 ( 173c 217 ( 56d
F286W 0.3 ( 0.1c 49 ( 2d 1.31 ( 0.02 465 ( 56c 2091 ( 662c
I287W 0.64 ( 0.06d 45 ( 3d 1.34 ( 0.08 785 ( 105c 1224 ( 129d
M288W 2.6 ( 0.6 17 ( 3 1.28 ( 0.04 672 ( 137b 259 ( 18c
I289W 3 ( 27 6 ( 6d 1.24 ( 0.08 859 ( 262c 339 ( 79b
L290W 3 ( 0.8 18 ( 2 1.13 (0.08 1797 ( 345 915 ( 202
V291W 1.1 ( 0.4c ND ND 182 ( 51d 158 ( 41d
A292W 1.3 ( 0.1b ND ND 83 ( 17c 67 ( 18d
F293W 2.3 ( 0.3 16 ( 3 1.2 ( 0.1 1158 ( 139b 477 ( 28
S294W 1.6 ( 0.2b 6.5( 0.5d 1.1 ( 0.1 2065 ( 229c 1301 ( 82d
V295W 0.4 ( 0.1c 8.3( 0.6d 1.8 ( 0.4 1217 ( 241b 4201( 1240d
I296W 0.26 ( 0.06d ND ND ND (3 of 7) 107 ( 26
I289W/F293W NE ND ND ND ND
a Four to twelve oocytes were used for each set of voltage clamp experiments and R-BuTX binding. Values are expressed as the mean ( the
standard error. The normalized response for each oocyte was obtained from the ACh-induced current at 300 íM divided by the femtomoles within
the same oocyte. ND ) no detectable current; NE ) no expression. b p < 0.01. c p < 0.05. d p < 0.001.
FIGURE 1: Macroscopic-current responses of wild type and âM3
mutants. Families of macroscopic currents derived from individual
Xenopus oocytes for (A) wild type and each of the following âM3
mutants: (B) R282W; (C) Y283W; (D) L284W; (E) M285W; (F)
F286W; (G) I287W; (H) M288W; (I) I289W; (J) L290W; (K)
V291W; (L) A292W; (M) F293W; (N) S294W; (O) V295W.
Currents were recorded using a two-electrode voltage clamp, as
described in MATERIALS AND METHODS. ACh-induced cur-
rents were detected at a membrane potential of -70 mV, digitized
at 4 kHz and filtered at 2 kHz. The ACh concentrations used to
generate the families of currents were 1, 3, 10, 30, 100, and 300
íM. After the macroscopic currents were recorded, the level of
AChRs expressed at the oocyte surface was normalized to the
surface R-BTX binding for each individual oocyte. The corre-
sponding expression levels of AChRs for each individual oocyte
tested are shown for each family of currents (in femtomoles).
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âTM3 mutants. None of the mutants produced peak currents
larger than that of wild type. However, five of the mutants
exhibited significantly higher normalized macroscopic cur-
rents, as compared to wild type (606 nA/fmol): R282W
(2506 nA/fmol), F286W (2091 nA/fmol), I287W (1224 nA/
fmol), S294W (1301 nA/fmol), and V295W (4201nA/fmol).
On the other hand, three of the mutants showed significantly
reduced normalized responses: M285W (217 nA/fmol),
M288W (259 nA/fmol), and I289W (339 nA/fmol). The
remaining three mutants, V291W, A292W, and I296W,
exhibited extremely small currents.
Effects of Mutations on the EC50 and Hill Coefficient
Values for ACh. ACh dose-response curves for the âM3
mutations are shown in Figure 2. The EC50 values for wild
type and the various âM3 mutants are shown in Table 1.
The R282W, L284W, M285W, F286W, I287W, and I289W
mutants exhibited 2- to 3-fold higher EC50 values for ACh,
as compared to wild type. The EC50 values of Y283W,
M288W, L290W, and L293W were similar to that of wild
type. Only two of the mutants, S294W and V295W, had EC50
values that were significantly lower than that of wild type.
The decreased EC50 for ACh exhibited by the S294W and
V295W mutants is consistent with the increased normalized
response of these mutants. The EC50 and Hill coefficient
values could not be estimated for the V291W, A292W, and
I296W mutants, due to the extremely low currents exhibited
by these receptors. No significant changes in the Hill
coefficients were observed in any of the other twelve
mutants, as compared to wild type. These results indicate
that these mutations do not alter the cooperativity of ACh
binding to the AChR.
DISCUSSION
Previous studies demonstrated that tryptophan substitution
at lipid-exposed positions dramatically affects the macro-
scopic response and channel gating kinetics of the AChR
(21-26, 28). In the current study, [125I-R-BTX] binding
analysis of wild type and mutant AChR expression in X.
laeVis oocytes demonstrated that tryptophan residues can be
accommodated along the âTM3 domain except at position
I296.
Functional Interpretation. Our previous studies showed
that tryptophan substitutions at lipid-exposed positions within
the RM4 (21-22, 26), çM3 (28), and RÆM3 (30, 35)
domains can significantly increase the normalized macro-
scopic response of the AChR. None of the tryptophan
mutants generated in the present study produced peak
currents larger than that of wild type. Tryptophan substitu-
tions at five positions of the âM3 transmembrane segment
(R282W, F286W, I287W, S294W, and V295) induced an
apparent increase in the normalized response of the AChR
(Table 1). Mutations R282W, F286W, and I287W exhibited
EC50 values higher than that of wild type, suggesting a
diminished functional response. As shown in Table 1,
R282W, F286W, and I287W were expressed at much lower
levels (0.9, 0.3, and 0.64 fmol, respectively) than wild type.
In contrast, S294W and V295W exhibited EC50 values that
were significantly lower than that of the wild type receptor,
suggesting that these AChR mutations induce a gain-in-
function response. This result appears to be consistent with
the observed increase in macroscopic response; however,
single channel data analysis will be necessary to verify this
hypothesis. Tryptophan replacement at position M285, which
presumably faces the lipid environment (20), resulted in a
3-fold reduction in the normalized response. Interestingly,
only the M285W mutant exhibited a significant increase in
AChR expression levels, as compared to wild type.
In contrast to the aforementioned mutations, the V291W
and A292W mutations exhibited the largest reduction in
macroscopic current response among the various mutants in
this study (Figure 1). The average expression level for these
two mutants was >1.0 fmol, which is considerably higher
than that of mutants that exhibited the largest normalized
macroscopic responses (i.e., V295W, 0.43 fmol, and F286W,
0.34 fmol). Therefore, the tryptophan-induced increase in
side chain volume at positions V291 and A292 is likely to
impair normal channel gating. Although the V295W had the
highest normalized response among all the âÆM3 mutants,
the peak current (1217 nA) and expression level (0.4 fmol)
of this mutant were significantly lower than those of wild
type; therefore, this was considered to be an inhibitory
position. Independent photolabeling studies did not detect
labeling at this position (20), suggesting that it might face
neighboring transmembrane segments toward the interior of
the protein. According to the most recent AChR structure
(31), V295 partially faces toward the RÆM1 domain and is
less oriented toward the âÆM2 domain than V291.
FIGURE 2: Dose-response curves of wild type and âM3 mutant
AChRs. Data are expressed as ACh-induced currents (nA) per
femtomole of surface R-BTX binding sites. The inset shows dose-
response curves normalized to maximum current. (A, top) Dose-
response curves for oocytes expressing wild type and mutants
R282W to M288W. (B, bottom) Dose-response curves for oocytes
expressing wild type and mutants I289W to V295W. The current
values used were collected from peak currents at six ACh
concentrations (1-300 íM) and fitted using a curve of the form Y
) 100/[1 + (EC50/A)n]. For each ACh concentration, the standard
error of the mean ((SEM) was determined from four to twelve
individual oocytes in each group.
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higher normalized macroscopic responses observed in the
mutants discussed above are not necessarily due to their low
expression levels, because other mutants with similar expres-
sion levels (i.e., L284W) did not exhibit normalized re-
sponses that were higher than those of wild type. The data
that we have gathered thus far indicate that mutations within
TM3 and TM4 do not affect agonist binding nor do they
produce global changes in the AChR ion channel pore, as
they have no effects on single channel conductance, reversal
potentials, or calcium permeability (21-23, 30, 38).A
previous study by Dr. Gary Yellen’s group demonstrated that
the affinity of R-BTX binding to the AChR is not affected
by mutations within the agonist binding site (39). Thus, it is
very unlikely that R-BTX binding affinity is altered in
response to these mutations made within âÆM3. Accord-
ingly, the pattern of the normalized response seems to depend
on the mutant itself, rather than on variation in expression
levels. It is important to understand that the normalized
response is a measure of the ratio of the fraction of functional
surface AChRs to the total number of 125I-R-BTX-labeled
receptors (both silent and functional). It has been demon-
strated that the fraction of functional surface AChRs (Nf)t o
the total number of surface R-BTX-AChRs (both silent and
functional, or Nt) is much less than 1.0 in the chick ciliary
ganglion (40). Previously, we have hypothesized that a
particular mutation could alter the equilibrium between the
silent and functional pools of receptors (26), which could
explain the pattern of normalized responses observed for the
R282W, F286W, and I287W mutants. To test this hypothesis,
it is necessary to fully understand the factors that control
how receptors move between the silent and functional surface
pools of AChRs. In the present study, we used the normalized
macroscopic response as a quantitative measure of the
macroscopic response of AChR mutants. To demonstrate that
a particular mutant exhibits an increased or decreased
normalized macroscopic response, it will be necessary to
correlate single channel analysis with the macroscopic data.
Structural Interpretation. Figure 3A shows the periodicity
profile of changes in AChR expression levels as a function
of tryptophan replacement at various positions in the âTM3
transmembrane segment. The curve shows that the oscilla-
tions of periodicity are approximately 3.6 amino acids. As
shown in Figure 3A, the largest shift in expression levels
occurs in the second phase of the oscillatory diagram,
corresponding to positions 284, 285, and 286. This expression
pattern suggests that these residues (L284, M285, and F286)
are likely to exist in a tightly packed R-helical structure. It
is possible that residues 284-286 form a 310 R-helical
structure. After the first stretch of residues (284-286), there
are two other well-defined oscillations, 287-291 and 292-
295. These two oscillatory patterns are slightly less defined
than 284-286 but are still consistent with an R-helical
structure. Although the oscillatory profile strongly suggests
that the âÆM3 domain forms an R-helical structure, there
could be a small distortion in the center of the helix (phase
III in Figure 3A). It is possible that the flattened area in the
center of the helix is caused by a twist resulting from the
crossing angle of the âÆM3 helix with other neighboring
helices (41). Remarkably, residues that are exposed to the
membrane lipids (19-20) were found in all the upper phases
of the oscillatory pattern, including I (R282), II (M285), III
(I289), and IV (F293). Our current findings provide ad-
ditional experimental evidence for a potential R-helical
structure within the Torpedo âÆM3 domain. Mutants that
are expressed at lower levels are clustered on one side of a
postulated R-helical structure. As shown in the helical
diagram in Figure 3B, L284W, F286W, and I287W, which
were expressed at levels <15% of the wild type, are clustered
facing the opposite side of the F293, R282, I289, and M285
residues, which have been shown to be exposed to the lipid.
We considered the possibility that âÆM3 could have a
â-sheet structure; however, the data were not consistent with
a â-sheet structure for the following reasons. First, a
tryptophan substitution would be expected to increase
expression levels at alternate positions along the peptide
chain, and this was not observed. Second, in a â-structure,
a residue like V291W must be oriented toward the lipid
environment, as are M285, I289, and F293. The V291W
residue is actually located in the lower side of phase III
(Figure 3A). Taken together, our data and previous photo-
FIGURE 3: (A) Periodicity of changes in expression of AChR as a
function of tryptophan substitution in the âM3 transmembrane
segment. Individual sets of data for the expression of each âM3
AChR mutant are shown as boxes, expressed as average femtomoles
( SEM. The curves display an oscillation with a periodicity of
approximately 3.6 amino acids. The gray bar represents 3.6 amino
acids, and the dashed line represents the wild-type expression levels.
Roman numerals above the curve indicate the phases of the
periodicity profile. The plot of expression levels versus the mutant
position within âM3 was constructed using a cubic spline curve
regression function (Prism version 3.0, GraphPAD Software). The
periodicity value was estimated by performing the first derivative
for each amino acid position and estimating the distance between
the zeros for all positions using Graph Pad Software. Each point
on the Y-axis represents an average of a number of measurements
(see Table 1). (B) Helical wheel diagram (view from top) for an
R-helical representation (3.6 amino acids per turn) of the âM3
showing the location of steric, constraint, inhibitory, and lipid-
exposed positions (20) according to the present mutagenesis study.
Positions at which tryptophan substitution results in relatively
normal AChR expression levels compared to wild type, including
M285, I289, and F293, are oriented toward the same face of the
R-helix. The asterisk (*) indicates that the residue was presumably
exposed to the lipid environment, as demonstrated by independent
photolabeling studies (20).
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with a â-sheet structure.
Constraint and Steric Sites. The I296W mutant exhibited
remarkably low expression levels (see Table 1), suggesting
that there is a structural constraint at this position that is
critical for receptor assembly and/or oligomerization. The
lack of ion channel function in this mutant is likely to result
from problems with receptor assembly. The present data
suggest that there is a structural constraint in I296W that is
critical for assembly and oligomerization of the receptor;
therefore, we designated this position as a constraint site.
Previously, we found a similar structural constraint at position
I417 in the TM4 transmembrane segment of the R subunit
of T. californica (26). The most recent structural model for
the transmembrane segments of the AChR (31) suggests that
position I296 is oriented toward the RÆM1 transmembrane
segment of one of the R-subunits in the closed state of the
channel (see Figure 4B and C). It is possible that the increase
in volume produced by a tryptophan substitution at position
I296 could produce a structural constraint with residues of
the RÆM1 domain. For example, according to the recently
proposed AChR structure (31), residue L224 in the RÆM1
domain could exist in very close proximity to a tryptophan
at I296.
At positions L284, F286, I287, and V295 (see Table 1), a
tryptophan substitution decreased AChR expression levels
to <15% of that of wild type, suggesting that receptor
assembly and perhaps oligomerization are significantly
affected by increases in side chain volume at these positions.
In contrast, tryptophan substitutions at positions V291 and
A292 resulted in significant reduction of AChR expression,
but these mutations appeared to dramatically inhibit ion
channel function. Therefore, we designated V291 and A292
as steric positions. Unlike the I296 position, V291 and A292
are oriented toward the interior of the protein (see Figure
4B), facing an open crevice in proximity to the M2 domain
(31). The orientation of these two residues toward the ion
channel domain is consistent with the remarkable inhibition
of AChR channel function observed for the V291W and
A292W mutants. Figure 4 shows the orientation of V291
and A292 (shown in yellow) according to the recent AChR
structure (31) from top and side orientations. The periodicity
analysis of the âM3 (Figure 3) predicts an R-helical structure,
as shown in Figure 4A. The biochemical and electrophysi-
ological characterization of these âÆM3 mutants is consistent
with an R-helical structure, and this is also consistent with
the recently proposed nAChR structure (31). Furthermore,
the electrophysiological characterization of the present muta-
tions defined positions within the âÆM3 domain that are
critical for AChR assembly and function.
ACKNOWLEDGMENT
We especially thank Jose ´ Reyes for his help in the
construction of these mutants and Dr. Alejandro Ortiz-
Acevedo for assistance with the molecular modeling and
structural interpretation.
REFERENCES
1. Pradier, L., and McNamee, M. G. (1992) The nicotinic acetyl-
choline receptor, in The Structure of Biological Membranes
(Yeagle, P., Ed.) 1st ed., pp 1047-1106, Telford Press, New
Jersey.
2. Unwin, N. (1993) Nicotinic acetylcholine receptor at 9 Å resolu-
tion, J. Mol. Biol. 229, 1101-1124.
3. Karlin, A., and Akabas, M. H. (1995) Toward a structural basis
for the function of nicotinic acetylcholine receptors and their
cousins, Neuron 15, 1231-44.
FIGURE 4: Structural model of the âM3 domain of the Torpedo californica AChR according to the present study (A) and according to a
recent structure by Miyazawa et al. (2003) (B and C). (A) Molecular modeling from the extended conformation of the âM3 domain starting
at positions 282 through L304 using a clockwise rotation and 3.6 amino acids per helical turn. (B) Helical view from the top. (C) Side view
of the âM3 according to ref 31. Labeled residues in blue (R282, M285, I289, and F293) have been shown to be in contact with the lipid
interface (20). Steric positions V291 and A292 are shown in yellow, and constraint position I296 is shown in green (in parts B and C
hydrogens on side chains are not shown).
Tryptophan Scanning of â Subunit Biochemistry, Vol. 43, No. 31, 2004 100694. Arias, H. R. (1998) Binding sites for exogenous and endogenous
non-competitive inhibitors of the nicotinic acetylcholine receptor,
Biochim. Biophys. Acta 1376, 173-220.
5. Changeux, J. P., and Edelstein S. J. (1998) Allosteric receptors
after 30 years, Neuron 21, 959-980.
6. Noda, M., Takahashi, H., Tanabe, T., Toyosata, M., Kikyotani,
S., Furutani, Y., Hirose, T., Takashima, H., Inayama, S., Miyata,
T., and Numa, S. (1983) Structural homology of Torpedo
californica acetylcholine receptor subunits, Nature (London) 302,
528-532.
7. Dipaola, M., Czajkowski, C., and Karlin, A. (1989) The sidedness
of the COOH terminus of the acetylcholine receptor delta subunit,
J. Biol. Chem. 264, 15457-15463.
8. Giraudat, J., Dennis, M., Heidmann, T., Chang, J. Y., and
Changeux, J. P. (1986) Structure of the high-affinity binding site
for noncompetitive blockers of the acetylcholine receptor: serine-
262 of the delta subunit is labeled by [3H]chlorpromazine, Proc.
Natl. Acad. Sci. U.S.A. 83, 2719-2723.
9. Giraudat, J., Dennis, M., Heidmann, T., Hamont, P. Y., Lederer,
F., and Changeux, J. P. (1987) Structure of the high-affinity
binding site for noncompetitive blockers of the acetylcholine
receptor: [3H]chlorpromazine labels homologous residues in the
beta and delta chains, Biochemistry 26, 2410-2418.
10. Giraudat, J., Gali, J., Revah, F., Changeux, J. P., Haumont, P.,
and Lederer, F. (1989) The noncompetitive blocker [3H]chlor-
promazine labels segment M2 but not segment M1 of the nicotinic
acetylcholine receptor alpha-subunit, FEBS Lett. 253, 190-198.
11. Hucho, F., Oberthur, W., and Lottspeich, F. (1986) The ion channel
of the nicotinic acetylcholine receptor is formed by the homolo-
gous helices M II of the receptor subunits, FEBS Lett. 205, 137-
142.
12. Imoto, K., Methfessel, C., Sakmann, B., Mishina, M., Mori, Y.,
Konno, T., Fukuda, M., Kurasaki, M., Bujo, H., Fujita, Y., and
Numa, S. (1986) Location of a delta-subunit region determining
ion transport through the acetylcholine receptor channel, Nature
324, 670-674.
13. Imoto, K., Busch, C., Sakmann, B., Mishina, M., Konno, T., Nakai,
J. M., Bujo, H., Mori, Y., Fukuda, M., and Numa, S. (1988). Rings
of negatively charged amino acids determine the acetylcholine
receptor channel conductance, Nature 335, 645-648.
14. Imoto, K., Konno, T., Nakai, J., Wang, F., Mishina, M., and Numa,
S. (1991) A ring of uncharged polar amino acids as a component
of channel constriction in the nicotinic acetylcholine receptor,
FEBS Lett. 289, 193-200.
15. Charnet, P., Labarca, C., Leonard, R. J., Vogelaar, N. J., Czyzyk,
L., Gouin, A., Davison, N., and Lester, H. A. (1990) An open-
channel blocker interacts with adjacent turns of alpha-helices in
the nicotinic acetylcholine receptor, Neuron 4,8 7 -95.
16. White, B. H., and Cohen, J. B. (1992) Agonist-induced changes
in the structure of the acetylcholine receptor M2 regions revealed
by photoincorporation of an uncharged nicotinic noncompetitive
antagonist, J. Biol. Chem. 267, 15770-15783.
17. Villarroel, A., and Sakmann, B. (1992) Threonine in the selectivity
filter of the acetylcholine receptor channel, Biophys. J. 62, 196;
205-208.
18. Akabas, M. H., and Karlin, A. (1995) Identification of acetylcho-
line receptor channel-lining residues in the M1 segment of the
alpha-subunit, Biochemistry 34, 12496-12500.
19. Blanton, M. P., and Cohen, J. B. (1992) Mapping the lipid-exposed
regions in the Torpedo californica nicotinic acetylcholine receptor,
Biochemistry 31, 3738-3750.
20. Blanton, M. P., and Cohen J. B. (1994) Identifying the lipid-
protein interface of the Torpedo nicotinic acetylcholine receptor:
secondary structure implications, Biochemistry 33, 2859-2872.
21. Lee, Y.-H., Li, L., Lasalde, J. A., Rojas, L. V., McNamee, M.,
Ortiz-Miranda, S. I., and Pappone, P. (1994) Mutations in the M4
domain of Torpedo californica acetylcholine receptor dramatically
alter ion channel function, Biophys. J. 66, 646-653.
22. Lasalde, J. A., Tamamizu, S., Butler, D. H., Vibat, C. R. T., Hung,
B., and McNamee, M. G. (1996) Tryptophan substitutions at the
lipid-exposed transmembrane segment M4 of Torpedo californica
acetylcholine receptor govern channel gating, Biochemistry 35,
14139-14148.
23. Ortiz-Miranda, S. I., Lasalde, J. A., Pappone, P. A., and McNamee,
M. G. (1997) Mutations in the M4 domain of the Torpedo
californica nicotinic acetylcholine receptor alter channel opening
and closing, J. Membr. Biol. 158,1 7 -30.
24. Bouzat, C., Roccamo, A. M., Garbus, I., and Barrantes, F. J. (1998)
Mutations at lipid-exposed residues of the acetylcholine receptor
affect its gating kinetics, Mol. Pharmacol. 54, 146-153.
25. Tamamizu, S., Lee, Y.-H., Hung, B., McNamee, M. G., and
Lasalde-Dominicci, J. A. (1999) Alteration in ion channel function
of mouse nicotinic acetylcholine receptor by mutations in the M4
transmembrane domain, J. Membr. Biol. 170, 157-164.
26. Tamamizu, S., Guzma ´n, G., Santiago, J., Rojas, L. V., McNamee,
M. G., and Lasalde-Domicci, J. A. (2000) Functional effects of
periodic tryptophan substitutions in the alpha M4 transmembrane
domain of the Torpedo californica nicotinic acetylcholine receptor,
Biochemistry 39, 4666-4673.
27. Wang, H. L., Milone, M., Ohno, K., Shen, X., Tsujino, A.,
Batocchi, A. P., Tonali, P., Brengman, J., Engel, A. G., and Sine,
S. M. (1999) Acetylcholine receptor M3 domain: stereochemical
and volume contributions to channel gating, Nature Neurosci. 2,
226-233.
28. Cruz-Martin, A., Mercado, J. L., Rojas, L. V., McNamee, M. G.,
and Lasalde-Dominicci, J. A. (2001) Tryptophan substitutions at
lipid-exposed positions of the gamma M3 transmembrane domain
increase the macroscopic ionic current response of the Torpedo
californica nicotinic acetylcholine receptor, J. Membr. Biol. 183,
61-70.
29. De Rosa, M. J., Rayes, D., Spitzmaul, G., and Bouzat, C. (2002)
Nicotinic receptor M3 transmembrane domain: position 8¢
contributes to channel gating, Mol. Pharmacol. 62, 406-414.
30. Navedo, M., Nieves, M., Rojas, L., and Lasalde-Dominicci, J.
(2004) Tryptophan substitutions reveal the role of nicotinic
acetylcholine receptor alpha-TM3 domain in channel gating:
differences between Torpedo and muscle-type AChR, Biochem-
istry 43,7 8 -84.
31. Miyazawa, A., Fujiyoshi, Y., and Unwin, N. (2003) Structure and
gating mechanism of the acetylcholine receptor pore, Nature 424,
949-955.
32. Go ¨rne-Tschelnokw, U., Strecker, A., Kaduk, C., Naumann, D.,
and Hucho, F. (1994) The transmembrane domains of the nicotinic
acetylcholine receptor contain alpha-helical and beta structures,
EMBO J. 13, 338-341.
33. Me ´thot, N., Ritchie, B. D., Blanton, M. P., and Baenziger, J. E.
(2001) Structure of the pore-forming transmembrane domain of
a ligand-gated ion channel, J. Biol. Chem. 276, 23726-23732.
34. Lugovskoy, A. A., Maslennikov, I. V., Utkin, Y. N., Tsetlin, V.
I., Cohen, J. B., and Arseniev, A. S. (1998) Spatial structure of
the M3 transmembrane segment of the nicotinic acetylcholine
receptor alpha subunit, Eur. J. Biochem. 255, 455-461.
35. Guzman, G. R., Santiago, J., Ricardo, A., Marti-Arbona, R., Rojas,
L V., and Lasalde-Dominicci, J. A. (2003) Tryptophan scanning
mutagenesis in the alphaM3 transmembrane domain of the
Torpedo californica acetylcholine receptor: functional and struc-
tural implications, Biochemistry 42, 12243-12250.
36. Ho, S. N., Hunt, H. D., Horton, R. M., Pullen, J. K., and Pease,
L. R. (1989) Site-directed mutagenesis by overlap extension using
the polymerase chain reaction, Gene 77,5 1 -59.
37. Pradier, L., Yee, A. S., and McNamee, M. G. (1989) Use of
chemical modifications and site-directed mutagenesis to probe the
functional role of thiol groups on the gamma subunit of Torpedo
californica acetylcholine receptor, Biochemistry 28, 6562-6571.
38. Gomez, C. M., Maselli, R. A., Groshong, J., Zayas, R., Wollman,
R. L., Cens, T., and Charnet, P. (2002) Active calcium accumula-
tion underlies severe weakness in a panel of mice with slow-
channel syndrome. J. Neurosci. 22, 6447-6457.
39. Tomaselli, G. F., McLaughlin, J. T., Jurman, M. E., Hawrot, E.;
Yellen, G. (1991) Mutations affecting agonist sensitivity of the
nicotinic acetylcholine receptor, Biophys. J. 60, 721-727.
40. McNerNey, M. L., Pardi, D., Pugh, P. C., Nai, Q., and Margiotta,
J. F. (2000) Expression and channel properties of alpha-bunga-
rotoxin-sensitive acetylcholine receptors on chick ciliary and
choroid neurons, J. Neurophysiol. 84, 1314-1329.
41. Treutlein, H. R., Lemmon, M. A., Engelman, D., Brunger, A. T.
(1992) The glycophorin A transmembrane domain dimer: Sequence-
specific propensity for a right-handed supercoil of helixes,
Biochemistry 31, 12726-12733.
BI0362368
10070 Biochemistry, Vol. 43, No. 31, 2004 Santiago et al.